Alnylam Pharmaceuticals welcomes Nobel Laureate Dr. Carolyn Bertozzi to its Board of Directors and announces Amy Schulman as new Board Chair

– USA, MA –  Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, today announced the appointment of  Nobel Laureate Dr. Carolyn Bertozzi (Ph.D.) to its Board of Directors.

Alnylam also announced the appointment of Board member and Lead Independent Director Amy Schulman to the role of Chair of the Board, succeeding Mike Bonney, who will remain on the Board as a non-independent director.

“We are thrilled to have Dr. Bertozzi’s perspectives on the Board. Dr. Bertozzi’s technical and leadership expertise will help Alnylam in our goal to serve more patients than ever before,” said CEO, Yvonne Greenstreet.

About Dr. Carolyn Bertozzi

Dr. Carolyn Bertozzi is known for her work in chemical biology. She is a pioneer for emerging technology and has founded ten biopharmaceutical companies and guided more than a dozen academic and professional organizations and life sciences companies in leadership and board positions.

“I am honored to support Alnylam’s ambitions to build a top-tier biopharmaceutical company based on the tremendous potential of RNAi therapeutics,” said Dr. Carolyn Bertozzi. “Alnylam has gained momentum launching new therapies and maximizing its pipeline based on proven technology, and I am looking forward to working with this esteemed team to help more people in need.”

Dr. Bertozzi is well-regarded as the founder of the bioorthogonal chemistry field and has co-founded multiple biopharmaceutical companies including Palleon Pharmaceuticals, InterVenn Bio, Grace Science, and Lycia Therapeutics. Dr. Bertozzi currently serves on the scientific advisory boards of Rayze Bio, Spotlight Therapeutics, and Ambigon Therapeutics, among others. Dr. Bertozzi also serves as the Baker Family Director of Stanford University’s Sarafan ChEM-H Institute, and as the Anne T. and Robert M. Bass Professor of Chemistry at the Stanford School of Humanities and Sciences. She is an investigator at the Howard Hughes Medical Institute, and a member of several venerable organizations, including the National Academy of Sciences, National Academy of Medicine, and National Academy of Inventors, as well as the Royal Society (UK), Accademia Nazionale dei Lincei and the German Academy of Sciences Leopoldina.

Dr. Bertozzi has been recognized with many distinctions, including a MacArthur Fellowship, the Lemelson-MIT Prize, the Welch Award in Chemistry, the Heineken Prize for Biochemistry and Biophysics, and the Wolf Prize in Chemistry. She has also been the Editor-in-Chief of ACS Central Science since 2014.

Mr. Bonney was appointed as Executive Chair of Alnylam in August 2021, having been elected to Alnylam’s Board of Directors in 2014. His experience leading the development and growth of successful, commercial-stage biopharmaceutical companies has helped Alnylam during a time of significant growth, and as the company sought to further strengthen its ethics and compliance function and integration with the business. During Mr. Bonney’s tenure in this role, he oversaw the appointment of Piyush Sharma, JD, as Alnylam’s new Chief Ethics and Compliance Officer.

Ms. Schulman was elected to the Alnylam Board of Directors in 2014. She is currently Managing Partner, Polaris Partners; Co-founder, Executive Chair, and former CEO of Lyndra Therapeutics; member of the Board of Directors of SQZ Biotech; and Senior Lecturer at Harvard Business School. Ms. Schulman sits on the board of Mount Sinai Hospital in New York.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet needs Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality.

Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile.

For more information, visit www.alnylam.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.